MARKET NEWS

VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor for the Treatment of Vitiligo
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 From Phase 1/2 BRILLIANCE Trial
Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1b Trial
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
ExCellThera Announces Completion of Phase 2 clinical Trials for UM171-Expanded Cell Therapy in High-Risk Blood Cancers
Tjoapack Strengthens its Injectables Offering With Addition of Prefilled Syringes Assembly & Packaging Services

  FEATURED EDITORIAL

  COMPANY PROFILE

One World DMG is a leading designer and manufacturer of injection trainers and patient onboarding materials for the pharmaceutical and biopharmaceutical industries. For 25 years we’ve pioneered the development of injection training tools that provide the most authentic injection experience possible. Our trainers have proven effective both in the medical setting and in patients’ homes, where comfort with self-injection is crucial to adherence and better health outcomes. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Evaxion Announces Promising Results From Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy

Evaxion Announces Promising Results From Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy

Evaxion Biotech A/S recently announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02….

Attralus & Ossianix Announce Option & License Agreement Using the TXP1 Brain Shuttle for Targeted Delivery of a Pan-Amyloid Removal Therapeutic for Neurodegenerative Disorders

Attralus & Ossianix Announce Option & License Agreement Using the TXP1 Brain Shuttle for Targeted Delivery of a Pan-Amyloid Removal Therapeutic for Neurodegenerative Disorders

Attralus, Inc. and Ossianix recently announced they have entered into a definitive agreement using Ossianix’ brain shuttle technology to enhance the targeted delivery of novel….

Meridian Medical Technologies & Kindeva Drug Delivery to Combine

Meridian Medical Technologies & Kindeva Drug Delivery to Combine

Meridian Medical Technologies recently announced it will combine with Kindeva Drug Delivery to create a leading global drug-device combination product Contract Development and….

Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China

Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China

Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunities….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

Manufacturing Phase 1 clinical material in as little as 12–16 months

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 7 – Drug Delivery
December 14 – Parenteral Contract Manufacturing